3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
28
Carcinoma, Non-Small-Cell Lung
28
Neoplasm Metastasis
23
Colorectal Neoplasms
19
Carcinoma, Hepatocellular
19
Triple Negative Breast Neoplasms
16
Pancreatic Neoplasms
15
Neoplasms
15
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
13
Nasopharyngeal Carcinoma
13
Carcinoma, Renal Cell
13
Uterine Cervical Neoplasms
10
Rectal Neoplasms
10
Lymphoma
8
Sarcoma
7
Esophageal Squamous Cell Carcinoma
7
Esophageal Neoplasms
7
Recurrence
6
Lymphoma, Extranodal NK-T-Cell
6
Lung Neoplasms
6
Locally Advanced Rectal Cancer
6
Breast Neoplasms
6
Advanced Solid Tumor
6
Ovarian Neoplasms
5
Glioblastoma
5
Endometrial Neoplasms
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Nasopharyngeal Neoplasms
4
Interventions
Cisplatin
76
Radiotherapy
44
pembrolizumab
39
Cetuximab
38
Paclitaxel
34
Carboplatin
33
Docetaxel
30
Fluorouracil
25
Radiotherapy, Intensity-Modulated
22
Nivolumab
18
Drug Therapy
14
Radiation
12
Erlotinib Hydrochloride
9
cemiplimab
8
Magnetic Resonance Spectroscopy
8
130-nm albumin-bound paclitaxel
8
durvalumab
7
atezolizumab
7
Cyclophosphamide
7
Afatinib
7
Surgical Procedures, Operative
6
Panitumumab
6
Leucovorin
6
Chemoradiotherapy
6
fludarabine
5
aldesleukin
5
Radiosurgery
5
Oxaliplatin
5
Methotrexate
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Squamous Cell
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts